Target intelligence / Profile preview

Sialic acid-containing glycoconjugates on human cell surfaces

Molecular classification
Other
01

Overview

Sialic acid-containing glycoconjugates, commonly referred to as sialoglycans, are complex sugar chains terminating in sialic acid residues that densely coat the surface of human cells, forming a major component of the cellular glycocalyx. These molecules play critical roles in physiological processes, including cell-cell recognition, cell adhesion, and immune system regulation. In healthy states, sialoglycans act as 'self' markers, interacting with sialic acid-binding immunoglobulin-like lectins (Siglecs) on immune cells to suppress inappropriate immune activation. However, in many cancers, tumor cells undergo hypersialylation, upregulating sialoglycans to exploit this pathway as a glyco-immune checkpoint, thereby evading both innate and adaptive immune surveillance.\n\nTherapeutic strategies targeting these cell surface sialoglycans focus on disrupting this immunosuppressive axis. Novel biotherapeutics, such as Palleon Pharmaceuticals' engineered human sialidase-Fc fusion proteins (e.g., E-602) and tumor-targeted sialidases (e.g., E-688/HLX316), enzymatically strip terminal sialic acids from the tumor and immune cell surfaces. This desialylation unmasks the tumor cells, preventing their interaction with inhibitory Siglec receptors and restoring robust anti-tumor immune responses. Additionally, specific monoclonal antibodies (such as FG129) are being developed to target tumor-associated sialoglycans for direct cell killing or payload delivery.

Other names
SialoglycansSialylated glycoconjugatesCell surface sialoglycansSialic acid-containing glycansSialylated glycoproteins and glycolipids
02

Mechanism of action

Enzymatic desialylation of cell surface glycans to disrupt sialoglycan-Siglec interactions and restore immune cell activation; targeted antibody binding to tumor-associated sialoglycans to induce cell death

03

Biological functions

Immune responseOther
04

Disease associations

CancerInflammationInfectionOther
05

Safety considerations

Off-target desialylation of healthy tissuesPotential transient hematological changesImmunogenicity of engineered fusion proteinsShort therapeutic half-life
06

Interacting drugs

E-602 (efgitasialase alfa)

4 more in the full profile.

07

Biomarkers

Tumor hypersialylation statusSialoglycan expression levelsSiglec ligand expression

Beyond the preview

Go deeper on Sialic acid-containing glycoconjugates on human cell surfaces.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sialic acid-containing glycoconjugates on human cell surfaces.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call